Development of the Parkinson’s disease gene therapy that UniQure was previously involved in...
- ViiV adds another innovative treatment to its growing HIV arsenal
- FDA expands Ibrance’s label to include male breast cancer patients
- Gilead submits sNDA to FDA to expand HIV label for Descovy
- NICE recommends BMS’ Opdivo-Yervoy combination for RCC
- ViiV announces long-term positive results for Juluca combination
Parkinson’s gene therapy development to restart in summer 2019
Development of the Parkinson’s disease gene therapy that UniQure was previously involved in will be restarted in a Phase II trial this summer with the help of a private-public entity.
Minerva to explore therapy in treatment-naïve schizophrenia and more
Minerva Neurosciences’ MIN-101 (roluperidone) is being considered for a future trial in treatment-naïve schizophrenia patients and additional indications with apathy symptoms.
ViiV adds another innovative treatment to its growing HIV arsenal
The FDA has approved Dovato (dolutegravir/lamivudine) for the treatment of human immunodeficiency virus (HIV) in adults who have not previously received antiretroviral therapy (ART).
Study shows CRISPR could help treat lung disease in utero
A proof-of-concept study by Penn Medicine and Children’s Hospital of Philadelphia (CHOP) in the US has offered hope for the treatment of lung diseases before birth by using CRISPR gene editing.
NIH strategy shows promise in hunt for universal influenza vaccine
On April 3, the US National Institutes of Health (NIH) announced the start of a Phase I clinical trial investigating the safety, tolerability, and immunogenicity of its universal influenza vaccine candidate, H1ssF_3928.
Excellent phase 3 trial data for rheumatoid arthritis drug filgotinib – but long road ahead
On 28 March 2019, Gilead and Galapagos announced that their selective JAK1 inhibitor, filgotinib, had met all primary endpoints in its two remaining Phase III rheumatoid arthritis (RA) trials, FINCH 1 and FINCH 3.
DNAnexus, Sutter Health and UPMC launch multiple sclerosis study
DNAnexus and Sutter Health have partnered with the University of Pittsburgh Medical Center to launch a clinico-genomic study aimed at improving personalised therapy for multiple sclerosis patients.
Agroceutical Products’ daffodils a boon to Alzheimer’s patients
Agroceutical Products, a bioresearch company based in Powys, Wales, is helping thousands of Alzheimer’s patients worldwide by supplying galantamine, a compound derived from daffodils that slows down the progression of Alzheimer’s symptoms.
Diagnosed prevalent cases of multiple myeloma on the rise
Common symptoms associated with multiple myeloma include bone pain, nausea and constipation.
Pfizer to use Concerto HealthAI technology for cancer treatments
Pfizer has partnered with patient-centred research firm Concerto HealthAI to fast-track actionable patient insights for investigational and commercialised cancer therapies.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.